BNP Paribas Arbitrage SA boosted its position in shares of Cardiovascular Systems Inc. (NASDAQ:CSII) by 39.4% during the third quarter, Holdings Channel reports. The institutional investor owned 5,445 shares of the medical device company’s stock after buying an additional 1,540 shares during the period. BNP Paribas Arbitrage SA’s holdings in Cardiovascular Systems were worth $129,000 as of its most recent filing with the SEC.
Several other large investors have also recently made changes to their positions in the stock. Menta Capital LLC boosted its position in shares of Cardiovascular Systems by 89.0% in the first quarter. Menta Capital LLC now owns 25,515 shares of the medical device company’s stock valued at $265,000 after buying an additional 12,015 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Cardiovascular Systems by 11.2% in the first quarter. Geode Capital Management LLC now owns 214,578 shares of the medical device company’s stock valued at $2,224,000 after buying an additional 21,543 shares during the last quarter. Wellington Management Group LLP boosted its position in shares of Cardiovascular Systems by 27.6% in the first quarter. Wellington Management Group LLP now owns 3,018,859 shares of the medical device company’s stock valued at $31,306,000 after buying an additional 652,962 shares during the last quarter. Bogle Investment Management L P DE bought a new position in shares of Cardiovascular Systems during the first quarter valued at about $2,796,000. Finally, Amici Capital LLC bought a new position in shares of Cardiovascular Systems during the first quarter valued at about $830,000. 68.16% of the stock is currently owned by institutional investors.
Shares of Cardiovascular Systems Inc. (NASDAQ:CSII) opened at 24.37 on Thursday. The company’s 50-day moving average is $24.10 and its 200-day moving average is $18.83. Cardiovascular Systems Inc. has a 52 week low of $7.50 and a 52 week high of $25.35. The firm’s market cap is $812.62 million.
Cardiovascular Systems (NASDAQ:CSII) last posted its quarterly earnings data on Wednesday, August 3rd. The medical device company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.05. The company had revenue of $48.50 million for the quarter, compared to analyst estimates of $46.01 million. Cardiovascular Systems had a negative net margin of 31.44% and a negative return on equity of 38.39%. The business’s quarterly revenue was up .0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.27) earnings per share. Analysts forecast that Cardiovascular Systems Inc. will post ($0.62) EPS for the current fiscal year.
Several research analysts have recently issued reports on CSII shares. Zacks Investment Research cut shares of Cardiovascular Systems from a “buy” rating to a “hold” rating in a report on Tuesday, July 5th. Needham & Company LLC upped their target price on shares of Cardiovascular Systems from $23.00 to $27.00 and gave the company a “buy” rating in a report on Thursday, August 4th. Leerink Swann upgraded shares of Cardiovascular Systems from a “market perform” rating to an “outperform” rating and set a $30.00 target price for the company in a report on Monday, August 22nd. JMP Securities began coverage on shares of Cardiovascular Systems in a report on Friday, October 7th. They issued an “outperform” rating and a $35.00 target price for the company. Finally, Bank of America Corp. upgraded shares of Cardiovascular Systems from an “underperform” rating to a “neutral” rating in a research note on Thursday, August 4th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Cardiovascular Systems currently has an average rating of “Buy” and an average target price of $27.40.
In other Cardiovascular Systems news, SVP Paul A. Koehn sold 4,000 shares of the business’s stock in a transaction on Wednesday, August 17th. The shares were sold at an average price of $22.17, for a total transaction of $88,680.00. Following the completion of the sale, the senior vice president now owns 102,652 shares in the company, valued at $2,275,794.84. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Camber Capital Management Llc sold 1,100,000 shares of the business’s stock in a transaction on Tuesday, September 20th. The shares were sold at an average price of $23.26, for a total transaction of $25,586,000.00. The disclosure for this sale can be found here. Insiders own 3.60% of the company’s stock.
Cardiovascular Systems Company Profile
Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary arterial diseases. It has developed an orbital atherectomy technology for peripheral and coronary commercial applications. Its peripheral arterial disease systems are catheter-based platforms that treat plaque types in leg arteries both above and below the knee.
Want to see what other hedge funds are holding CSII? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cardiovascular Systems Inc. (NASDAQ:CSII).
Receive News & Ratings for Cardiovascular Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems Inc. and related companies with MarketBeat.com's FREE daily email newsletter.